Back to results
US 2004/0006013 A1Published application
Histogranin peptide and their analgesic use
AssigneeUniversity of Ottawa
InventorSimon Lemaire
Life of this patent
Estimating the term…
Abstract
The invention relates to linear and cyclic peptide and pseudopeptide compounds useful as analgesics, pharmaceutical compositions comprising such compounds, the use of the compounds and the compositions in the treatment of pain, and commercial packages containing such compounds and compositions.
Claims12
A compound or Formula I:
- 10
- wherein
- R1 represents hydrogen, alkyl, alkenyl, alkynyl, —(CH2)n—NH2, —(CH2)n—NH—C(═NH)NH2, or
- 11
- wherein
- “n” is an integer from 0 to 10;
- R2 represents —(CH2)nCONH2, wherein “n” represents an integer from 0 to 10;
- R3 represents hydrogen, alkyl, alkenyl, alkynyl, the radical of formula:
- 12
- or the radical of formula:
- 13
- wherein
- “n” represents an integer from 0 to 10;
- and
- R11, R12 and R13 may be the same or different and represent hydrogen, alkyl, alkenyl, alkynyl, —I, —F, —Br, —Cl, or —OH;
- and
- R4 represents —(CH2)nNH2, —(CH2)nNHC(═NH)NH2, or
- 14
- wherein
- “n” represents an integer from 0 to 10;
- R5 and R9 may be the same or different and represent hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylamino, or —(CH2)naryl, wherein “n” is an integer from 1 to 10;
- R6, R7, and R8 may be the same or different and represent hydrogen, alkyl, alkenyl, or alkynyl;
- R10 represents hydroxy, alkoxy, alkenyloxy, alkynyloxy, amino, alkylamino, dialkylamino, alkylaryl, arylalkoxy, aryloxy, alkoxyaryl, A1, A1-A2, A1-A2-A3, A1-A2-A3-A4, or A1-A2-A3-A4-A5,
- wherein
- A1 represents threonine or serine;
- A2 represents leucine, glycine, alanine, valine, or isoleucine;
- A3 represents tyrosine, phenylalanine, or tryptophan;
- A4 represents glycine, alanine, leucine, isoleucine, or valine;
- and
- A5 represents phenylalanine, tyrosine, or tryptophan;
- pseudopeptide analogues thereof wherein ore or more of the carbonyl groups of the peptide linkage is replaced by —C(═S)— or by —CH2—, and/or wherein one or more of the amide bonds, —C(O)—NH—, is replaced by the retro-verso form, —NH—C(O)—, thereof;
- and
- pharmaceutically acceptable salts and esters thereof,
- with the proviso that the compound is not selected from the group comprising:
- 12 H-glycine-glutamine-glycine-arginine-threonine-leucine-tyrosine-glycine-phenylalanine-OH H-valine-glutamine-tryptophan-lysine-OH H-histidine-asparagine-leucine-lysine-OH H-leucine-glutamine-ψ(CS-NH)leucine-lysine-OH H-lysine-glutamine-phenylalanine-lysine-OH H-glycine-glutamine-leucine-lysine-OH
32 more elements
A compound selected from the group consisting of
- 13 H-Gly-Gln-Ala-Arg-OH, (SEQ ID NO:3) H-Arg-Gln-Ala-Arg-OH, (SEQ ID NO:4) cyclic (-Gly-Gln-Ala-Arg-), (SEQ ID NO:5) cyclic (SEQ ID NO:10) (-Gly-Gln-Ala-Arg-Gly-Gln-Ala-Arg-), cyclic(-Arg-Gln-Ala-Arg-), (SEQ ID NO:6) cyclic (SEQ ID NO:11) (-Arg-Gln-Ala-Arg-Arg-Gln-Ala-Arg-), cyclic(-Gly-Gln-Tyr-Arg-), (SEQ ID NO:7) cyclic(-Gly-Gln-Tyr-D-Arg-), cyclic(-Gly-D-Gln-Tyr-D-Arg-), H-Gly-Gln-Tyr-Arg-OH, (SEQ ID NO:8) H-Gly-Gln-Tyr-D-Arg-OH, and H-Gly-D-Gln-Tyr-D-Arg-OH.
A compound selected frog the group consisting of H-
- 14 (SEQ ID NO:
- 1) H-Arg-Gln-Gly-Arg-OH, (SEQ ID NO:
- 2) H-Gly-Gln-Gly-Arg-OH, and (SEQ ID NO:
- 9) H-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-OH 9. Cyclic (-Gly-Gln-Tyr-D-Arg-) 10. Cyclic (-Gly-D-Gln-Tyr-D-Arg-)
1 more element
Dependencies are inferred from the claim text.